DFD-29 rosacea treatment shows no significant impact on healthy, microbial flora

Journey Medical Corporation announced positive, topline results from its phase 1 clinical trial evaluating the impact of DFD-29 on the microbial flora of healthy adults, according to a company press release.“We are very pleased with the topline results of this Phase 1 clinical trial, indicating that DFD-29 can be safely used for up to 16 weeks with no significant risk of microbiota suppression or development of resistance” Claude Maraoui, president and CEO of Journey Medical Corporation, told Healio.DFD-29 is a 40 mg minocycline hydrochloride modified release capsule that isRead More